BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21708889)

  • 1. Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
    Riley CH; Jensen MK; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM
    Blood; 2011 Aug; 118(8):2170-3. PubMed ID: 21708889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
    Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
    Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC
    Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.
    Riley CH; Brimnes MK; Hansen M; Jensen MK; Hasselbalch HC; Kjaer L; Straten PT; Svane IM
    Eur J Haematol; 2016 Jul; 97(1):83-92. PubMed ID: 26385526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
    Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
    Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders.
    Bonaccorso R; Teresi M; Gebbia V; Tambone Reyes M; Tinnirello D; Di Marco P; Citarrella P; Mansueto S
    J Chemother; 1989 Jul; 1(4 Suppl):1266-8. PubMed ID: 16312860
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
    Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch HC; Holmström MO
    Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
    Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
    Hansen IO; Sørensen AL; Hasselbalch HC
    Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A; Elliott MA; Solberg LA; Silverstein MN
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.